US equities |
SPCX $168.79 ▲+6.18% NVDA $237.44 ▲+1.49% MU $1,066.00 ▼-0.83% TSLA $380.46 ▲+2.66% MSFT $525.43 ▲+1.53% SNDK $1,714.12 ▼-0.34% INTC $116.86 ▼-2.07% META $744.08 ▲+2.20%
FinancialContent

Articles published by MoonLake Immunotherapeutics AG

News headline image
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX
News headline image
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Tickers MLTX